5-Amino-1MQ

What it is

5-Amino-1MQ (5-amino-1-methylquinolinium, CAS 42464-96-0) is a small molecule rather than a peptide — worth stating plainly, since it sits alongside peptides in most catalogues. It selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that consumes nicotinamide and is markedly overexpressed in adipose tissue in obesity. Inhibiting NNMT spares nicotinamide for NAD+ synthesis, raising cellular NAD+ levels. Higher NAD+ availability activates the sirtuin pathway (SIRT1), which is associated with mitochondrial biogenesis and increased fat oxidation. The result in preclinical models is reduced adipocyte size and fat mass through altered energy handling rather than through appetite signalling.

The reported response is metabolic rather than appetite-driven. Cellular NAD+ rises, mitochondrial activity in fat and muscle tissue increases, and fat oxidation improves. Because appetite is not suppressed, there is no reduction in food intake to signal that the compound is working — which makes it a poor fit for anyone expecting the felt experience of a GLP-1. This is also why it is more usefully positioned as a stack partner to Retatrutide or Tirzepatide than as an alternative to them. Human data is limited; most of what is known comes from animal and cell studies.

• Reduced fat mass and adipocyte size in diet-induced obese mice without reduced food intake
• Increased cellular NAD+ and activation of SIRT1-associated pathways
• Improved metabolic parameters when combined with reduced-calorie feeding in preclinical models
• NNMT knockdown independently protects against diet-induced obesity — the target itself is well validated
• Human weight-loss evidence is not yet established — the fat-loss findings above are preclinical

Who it's for

• Metabolic support alongside a GLP-1 or GIP agonist protocol — a different mechanism, not a competing one
• Clients who want a fat-loss lever that does not act through appetite suppression
• NAD+-focused metabolic and longevity protocols
• Clients comfortable with a compound whose human evidence base is still early

• Competing athletes subject to anti-doping testing — see cautions
• Pregnancy or breastfeeding (no safety data)
• Clients expecting appetite suppression or GLP-1-comparable weight loss
• Clients who want an established human evidence base before starting

Protocol guidance

Contraindications & cautions

• Supply: at 2.5mg per day a 10mg vial is four days of material. A month requires roughly 7.5 vials. Plan and price the full cycle before starting, and speak to us about bulk pricing — this is not a one-vial compound.
• WADA-banned under category S0 (unapproved substances) — not permitted for any athlete subject to anti-doping testing
• Not registered with the FDA or any equivalent regulator
• Human data is limited; the weight-loss evidence is preclinical, and effect sizes in humans are unknown
• It is a small molecule, not a peptide — reconstitution and handling guidance differs from the peptides in this catalogue, so follow the guidance supplied with the vial

Pairs well with

Research